



Contents lists available at [SciVerse ScienceDirect](#)

Cancer Epidemiology

The International Journal of Cancer Epidemiology, Detection, and Prevention

journal homepage: www.cancerepidemiology.net



Review

Endotoxin and cancer chemo-prevention

Mastrangelo Giuseppe^a, Fadda Emanuela^a, Cegolon Luca^{a,b,*}

^aPadua University, Department of Molecular Medicine, Padua, Italy

^bImperial College London, School of Public Health, London, UK

ARTICLE INFO

Article history:

Received 5 April 2013

Accepted 23 April 2013

Available online xxx

Keywords:

Cancer

Endotoxin

Chemo-prevention

Epidemiology

Monophosphoryl lipid A

Allergy vaccine

ABSTRACT

Reduced rates of lung cancer have been observed in several occupational groups exposed to high levels of organic dusts contaminated by endotoxin. The underlying anti-neoplastic mechanism of endotoxin may be an increased secretion of endogenous anti-neoplastic mediators and activation of the toll-like receptors (TLR). A detoxified endotoxin derivative, Monophosphoryl Lipid A (MPL[®]) is marketed in Europe since 1999 as part of the adjuvant systems in allergy vaccines for treatment of allergic rhinoconjunctivitis and allergic asthma. Over 200,000 patients have used them to date (nearly 70% in Germany). Since detailed exposure (MPL[®] dose and timing of administration) and individual data are potentially available, an observational follow-up study could be conducted in Germany to investigate the protective effect of MPL[®] against cancer, comparing cancer incidence in two groups of patients with allergic rhinitis: those treated with allergoids plus MPL[®] and those treated with a vaccine including the same allergoids but not MPL[®]. The protective effect of MPL[®] could be quantified in ever and never smokers. If this proposed observational study provides evidence of protective effects, MPL[®] could be immediately used as a chemo-preventive agent since it is already in use as adjuvant in human vaccines against cancer.

© 2013 Elsevier Ltd. All rights reserved.

1. Background

1.1. Cancer mortality and incidence

The US age-standardized mortality rate per 100,000 for heart disease and cancer were, respectively, 492.7 vs.198.6 in 1970, and 173.7 vs. 168.6 in 2011 [1]. A scatter-plot of rates against years was built from 1993 to 2011 with a slope expressing the time trend. Fig. 1 shows that the time trends for cancer and heart disease are expected to converge after 2011, when cancer will likely become the leading cause of death. The crossover of cancer over heart disease mortality has been recently reported in New Zealand [2], France [3–5], Spain [3], Canada [6] and the Netherlands [7].

High-quality population-based cancer incidence data have been collected throughout the world since the early 1960s and published periodically in Cancer Incidence in Five Continents (CIS). The International Agency for Research on Cancer (IARC) has made these data available [8]. These data have been used in Fig. 2a (males) and b (females), to show the time trend of age-standardized (world) cancer incidence rates (all ages) from the first available to

the last available calendar year in 12 Western countries. A general upward trend over time appears in both figures.

Cancer is a major public health issue worldwide in both developed countries (where incidence rates are higher) and developing countries (where survival rates are lower). However, cancer incidence is increasing also in developing countries as a consequence of the globalization of economies/habits and the high frequency of cancers of infectious origin. The majority of patients diagnosed with cancer are likely to die for the disease sooner or later, and nevertheless their survival is inevitably going to impact the corresponding treatment costs. In the next future the cost will raise even more sharply because of the introduction of new targeted cancer treatments [9], particularly in countries such the US where a twofold increase of the elderly population is expected in the next decades [10].

1.2. Current preventive strategies against cancer

Although previous observational studies showed that cancer could be prevented by a high intake of fruits and vegetables, the European Prospective Investigation into Cancer and Nutrition cohort (142,605 men and 335,873 women) provided evidence of a very small inverse association between fruit and vegetable intake and cancer risk [9]. Likewise, in two prospective cohorts (71,910 women in the Nurses' Health study and 37,725 men in the Health Professionals' Follow-up Study) healthy eating based on a fruit and

* Corresponding author at: Imperial College London, School of Public Health, St. Mary's Campus, London W2 1PG, UK.

E-mail addresses: l.cegolon@gmail.com, l.cegolon10@imperial.ac.uk (L. Cegolon).




Fig. 1. Age adjusted (US standard population 2000) death rates per 100,000 for heart disease and malignant neoplasms. USA, both sexes, all ages and races, 1993–2010.

vegetable diet proved to be effective in reducing cardiovascular diseases but not cancer incidence [11,12].

Despite numerous advances in tobacco-dependence treatment, the U.S. adult smoking prevalence and quit rates have stalled [13–15]. According to Levy et al. [16] the annual smoking cessation without any intervention is estimated to be 4.3%, reaching a rate of 4.5–10% with corporate health education campaigns requiring great effort and resources. Furthermore relapse rates after cessation are reported to be as high as cessation according to Hughes et al. [17], Hajek et al. [18] and Anderson et al. [19]. Yet efforts to prevent teens from taking up smoking have shown no evidence of long term effectiveness [18,20], and ex-smokers continue to have an elevated risk of developing lung cancer [21].

Prevalence of binge and heavy drinking among adults in the United States has been practically constant from 1993 to 2009, with approximately 5% of the total population drinking heavily and 15% binge drinking [22]. This signifies that health education campaigns have failed to achieve significant public health outcomes in alcohol misuse reduction. According to Foxcroft et al. [23] no firm conclusions can be drawn on the effectiveness of short and medium term primary interventions to combat alcohol misuse in young people.

Despite the afore mentioned evidence, the International Union Against Cancer (UICC) still suggested in 2005 the same key areas for cancer prevention: smoking, alcohol misuse, obesity, sun exposure, and infections [24].

All the above calls for a revision of prevention strategies against cancer: a reduced incidence would indeed almost certainly translate directly into reduced mortality.

2. Discussion

2.1. Endotoxin and cancer

Endotoxin is an integral component of the outer wall of Gram-negative bacteria which grow on moist cellulose-rich materials (organic dusts). The more active component of endotoxin, lipopolysaccharide (LPS), is liberated when the bacteria die and the cell wall breaks apart [25,26]. Endotoxin is ubiquitous in indoor and outdoor environments, but the highest exposures have been measured in agricultural environments and cotton textile mills [27]. Exposure primarily occurs through inhalation of airborne endotoxins present in organic dusts (also termed bioaerosols).

Endotoxin exposure may cause acute and chronic health effects. However, epidemiological studies have also shown protective effects of environmental endotoxin exposure with regard to atopic

asthma and allergy in early childhood [28]. Another positive effect of endotoxin is suggested in the context of cancer: reduced rates of lung cancer have been observed in several occupational groups which are exposed to high levels of organic dusts contaminated by endotoxin.

A systematic review and meta-analysis was conducted on the large body of epidemiological data published on farmers and cotton textile workers [29]. The summary risk of lung cancer was 0.72 (95% Confidence Interval, CI = 0.57–0.90) in the latter (Fig. 3a) and 0.62 (95% CI: 0.52–0.75) (Fig. 3b) in the former.

In Italy exposure to endotoxin has never been measured in dairy stables. The number of dairy cattle in the farm was therefore used as a surrogate of exposure levels to endotoxin. An inverse relationship was observed between standardized mortality ratio or adjusted odds ratio for lung cancer and the number of dairy cattle in the farm [30,31]. The protective effect was no more discernible among farmers who had ceased working in dairy farms >15 years previously [31]. Concordant results were obtained for Finnish farmers [32].

One study from China [33] and another from Lithuania [34] provided quantitative estimates of endotoxin exposure and both studies tended to support a dose-dependent protective effect of endotoxin on lung cancer risk. In the large study on Chinese workers, cumulative exposure to endotoxin was inversely related to risks of lung cancer (p-trend = 0.004) [33] and also: esophageal cancer (p-trend = 0.01) [35]; stomach cancer (p-trend = 0.001) [35]; rectum cancer (p-trend = 0.08) [36]; liver cancer (p-trend = 0.02) [37]; pancreatic cancer (p-trend = 0.001) [38]; and breast cancer (p-trend = 0.001) [39].

The underlying anti-neoplastic mechanism of endotoxin may be an increased secretion of endogenous anti-neoplastic mediators (cytokines and tumor necrosis factor- α), and activation of the toll-like receptors (TLR) [40] (see Fig. 4). TLRs are intracellular and cell surface proteins of the innate immune system that are capable of recognizing pathogen-specific molecules; TLRs are expressed by several immune cells including dendritic cells (DC) where they act as a master regulatory switch and play an important role in reversing the immune tolerant effects of T cells.

2.2. Monophosphoryl lipid A (MPL[®])

The biologically active component of endotoxin is lipid-A whose structure is shown in Fig. 5. By removing specific phosphate groups as well as the sugar moieties, a detoxified derivative, Monophosphoryl Lipid A (MPL[®]), has been obtained, which has retained immunostimulatory activities on dendritic cells (TLR4 agonist).

MPL[®] is marketed in Europe for allergy treatment because of its ability to enhance Th1 response to responses to allergens, hence suppressing the development of allergy and asthma. A range of ultra-short course MPL[®]-based subcutaneous allergy vaccines has been developed which requires the administration of only four injections before the start of the pollen season. Successful preliminary double-blind placebo controlled studies on these vaccines have already been conducted and, as a consequence, these products have been marketed since 1999 in Europe (nearly 70% in Germany) and other countries. Over 200,000 patients have used them to date [41].

As substantial exposure data are available from the named patient program (named patient products), product reviews have been carried out, at least in Canada [42] and New Zealand [43]. MPL[®] adjuvant is safe, well-tolerated and potent, and has been given to millions of individuals. MPL[®] is in fact already in use as adjuvant agent in human vaccines for cancer therapy (melanoma, cervical cancer, HER2-positive breast carcinoma, prostate cancer, colorectal carcinoma, MAGE-3-Expressing Cancers, STn-Expressing Carcinomas, MUC1-expressing cancers and RAS-expressing




Fig. 2. (a) All-sites but non-melanoma skin tumors in males aged 0–85+ years: age-standardized incidence rates (World) in 12 selected Western countries. (b) All-sites but non-melanoma skin tumors in females aged 0–85+ years: age-standardized incidence rates (World) in 12 selected Western countries.

tumors [44,45]) and prevention (immunization against oncogenic human viruses: hepatitis B virus and papilloma virus).

2.3. Study design and power considerations

An observational follow-up study could allow a rapid investigation on the protective effect of MPL[®] against cancer, comparing cancer incidence in two groups of patients with allergic rhinitis:

- one treated with allergen plus TLR4 agonist;
- another group treated with a vaccine including the same allergen but not the TLR4 agonist.

Since detailed exposure (MPL[®] dose and timing of administration) and individual data are potentially available, the protective effect of TLR4 agonist could be quantified in those who have ever or never smoked.

According to Globocan [8], the incidence rates ($\times 10^{-5}$) for all site cancers (excluding skin) in more developed countries in 2002 were 61.9 and 93.9 respectively in males and females, both in the range of 15–44 years (ages at higher risk of allergic rhinitis).

Assuming that:

- out of 200,000 who received an allergy vaccine including TLR4 agonist, 70% ($140,000 = 200,000 \times 0.7$) reside in Germany;




Fig. 3. (a) Lung cancer risk in cotton workers: a meta-analysis. (b) Lung cancer risk in farmers: a meta-analysis (from reference 29, adapted)




Fig. 4. Mechanisms of endotoxin-mediated anti-cancer effects.

10,000 of the above 140,000 patients have no data available or are lost to follow up, for a final number of 130,000;

- the time window of observation could be from 1999 to 2010, if the follow up registers (e.g.: the national register of hospital discharge forms) are updated to 2010;
 - a linkage between the exposure and follow up registers is feasible;
 - the average number of years of observation would be 6 $[(2010-1999)/2]$ and the person-years around 780,000 $(=130,000 \times 6)$;
 - gender difference among the above 130,000 patients is negligible, the person years would therefore be 390,000, equal for males and females;
 - treatment with MPL reduces by 25% the risk of all site cancers (excluding skin);
- then, the expected cases of cancer would be:
- 241 among males exposed $(=390,000 \times 61.9 \times 10^{-5})$ and 366 $(=390,000 \times 93.9 \times 10^{-5})$ among females exposed, for a total number of 607 expected cases in this cohort;
 - 152 $(=607 \times 0.25)$ would be the cases of cancer prevented by TLR4 agonist, hence the observed cases in the cohort would be 455 $(=607-152)$;




Fig. 5. Lipid A (on the left) and the detoxified derivative (on the right).

- the lower and upper 95% confidence limits for 455 are 409 and 494 respectively according to the Poisson distribution.

The observed/expected ratio would be 0.75 (=455/607), with lower 95% CI equal to 0.67 (=409/607) and the upper 95% CI equal to 0.81 (=494/607). Therefore the treatment effect would be significant with $p < 0.05$.

3. Summary

A positive result of such a study could support the implementation of a future cancer prevention trial in high risk individuals. Since a lower incidence of cancer translates directly into lower mortality [46], this study could therefore be relevant.

Lundin and Checkoway [47] have recently reviewed epidemiologic, clinical trial, and experimental studies pertinent to the hypothesis that endotoxin prevents cancer. Since the 1970s, epidemiologic studies on cotton textile and other endotoxin-exposed occupational groups have consistently demonstrated reduced lung cancer risks. Experimental animal toxicology research and some limited therapeutic trials in cancer patients offer additional support for an anti-cancer potential. The underlying biological mechanisms of anti-carcinogenesis are not entirely understood but are thought to involve the recruitment and activation of immune cells and pro-inflammatory mediators (e.g., tumor necrosis factor alpha and interleukin-1 and -6). They concluded that in view of the current state of knowledge, it would be premature to recommend endotoxin as a cancer chemo-preventive agent. Nonetheless, further epidemiologic and experimental investigations that can clarify further dose-effect and exposure-timing relations would provide substantial public health and basic biomedical benefits.

In an Editorial on the Journal of the National Cancer Institute, Boffetta [48] pointed out that the implementation of an endotoxin-based intervention against lung cancer requires knowledge of:

1. which endotoxin (if any) exerts a chemo-preventive effect;
2. the underlying mechanism of action;

3. the protective effect of endotoxin exposure in smokers (including ex-smokers);
4. the potential health risks of endotoxin administration.

The proposed project may give a satisfactory response to the above queries no. 1 and no. 3. Lastly the potential health risks linked to MPL[®] administration (query 4) have already been investigated in some studies [42,43,49] where the findings have provided no evidence of harmful side effects.

The National Cancer Institute (NCI) and the Food and Drug Administration (FDA) have developed general strategies for new chemo-preventive agents. This typically involves the initial in vitro studies, progressing to animal carcinogenesis studies and then concluding with phased human trials [50]. However, since MPL[®] is already in use in human vaccines against cancer [44], this TLR-4 ligand could be immediately used as a chemo-preventive agent if the above proposed observational study provides evidence of protective effects.

Conflicts of interest statement

None to declare.

References

- [1] National Vital Statistics Reports. Available at: <http://www.cdc.gov/nchs/products/nvsr.htm> (accessed in January 2013).
- [2] New Zealand Health Information and Service. Mortality and demographic data 2002 and 2003. Ministry of Health; 2006. Available at: <http://www.nzhis.govt.nz/moh.nsf/pagesns/528> (accessed in January 2013).
- [3] WHO Europe. Highlights on health in France; 2004. Available at: www.euro.who.int/_data/assets/pdf_file/0020/103853/E88547.pdf (accessed in January 2013).
- [4] WHO Global Infobase: proportional mortality. Available at: <https://apps.who.int/infobase/Mortality.aspx> (access in January 2013).
- [5] Aouba A, Péquignot F, Le Toullec A, Jouglu E. Les causes médicales de décès en France et leurs évolutions récentes, 1980–2004. *Bul Epidemiol Hebd* 2007;35–36:308–14. Available at: http://www.parisnord.idf.inserm.fr/paris7/fr/recherche_pour_tous/ComprendreAtlas_de_la_mortalite_par_cancer.html (accessed in January 2013).
- [6] Statistics Canada. Available at: www.statcan.gc.ca (accessed in January 2013).
- [7] Statistics Netherlands. Cancer number one cause of death in 2008. Available at: www.cbs.nl/enGB/menu/themas/gezondheidwelzijn/publicaties/artikelen/archief/2009/2009-2687-wm.htm (accessed in January 2013).

- [8] International Agency for Research on Cancer (IARC). Globocan 2008. Available at: <http://globocan.iarc.fr/> (accessed in January 2013).
- [9] Mariotto AB, Yabroff KB, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. *JNCI* 2011;103:117–23.
- [10] U.S. Census Bureau. Population division: interim projections consistent with census 2000 (released March 2004). Washington D.C.: U.S. Census Bureau, Population Division, 2008 (accessed July 2008) <http://www.census.gov/population/www/projections/usinterimproj/>.
- [11] Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, et al. Fruit and vegetable intake and overall cancer risk in the European prospective investigation into cancer and nutrition (EPIC). *J Natl Cancer Inst* 2010;102:529–37.
- [12] Hung HC, Joshupura KJ, Hu FB, Hunter D, Smith-Warner SA, Colditz GA, et al. Fruit and vegetable intake and risk of major chronic disease. *J Natl Cancer Inst* 2004;96(21):1577–84.
- [13] Abrams D. Comprehensive smoking cessation policy for all smokers: systems integration to save lives and money. In: Bonnie RJ, Stratton K, Wallace RB, eds. Ending the tobacco problem: a blueprint for the nation. Washington: The National Academies Press, 2007.
- [14] Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains—in our lifetime. *Am J Prev Med* 2007;33(6S):S340–8.
- [15] Gollust S, Schroeder S, Warner K. Helping smokers quit: understanding the barriers to utilization of smoking cessation services. *Millbank Q* 2008;86(4):601–27.
- [16] Levy TD, Graham AL, Mabry PL, Abrams DB, Orleans TB. Modeling the impact of smoking-cessation treatment policies on quit rates. *Am J Prev Med* 2010;38(3S):S364–72.
- [17] Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. *Addict Behav* 2008;33(12):1516–20.
- [18] Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation (Review). *Cochrane Libr Issue* 1 2009. Available at: www.thecochranelibrary.com (accessed in January 2013).
- [19] Anderson CM, Yip R, Henschke CI, Yankelevitz DF, Ostroff JS, Burns DM. Smoking cessation and relapse during a lung cancer screening program. *Cancer Epidemiol Biomarkers Prev* 2009;18(12):3476–83.
- [20] Wiehe SE, Garrison MM, Christakis DA, Ebel BE, Rivara FP. A systematic review of school-based smoking prevention trials with long-term follow-up. *J Adolesc Health* 2005;36:162–9.
- [21] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. *CA. Cancer J Clin* 2008;58:71–96.
- [22] Center for Diseases Prevention and Control (CDC) website. Alcohol & Public Health. Available at: www.cdc.gov/alcohol/ (accessed in January 2013).
- [23] Foxcroft DR, Ireland D, Lister-Sharp DJ, Lowe G, Breen R. Longer-term primary prevention for alcohol misuse in young people: a systematic review. *Addiction* 2003;98(4):397–411. Review.
- [24] UICC (2005). Cancer can be prevented too. Available at: http://www.worldcancercampaign.org/index.php?option=com_content&task=view&id=273&Itemid=586 (accessed in January 2013).
- [25] Hiene H, Rietschel T, Ulmer AJ. The biology of endotoxin. *Mol Biotechnol* 2001;19:279–96.
- [26] Ulmer A. Biochemistry and biology of endotoxins. *Int J Occup Environ Health* 1997;3(Suppl.):S8–17.
- [27] Liebers V, Brüning T, Raulf-Heimsoth M. Occupational endotoxin-exposure and possible health effects on humans. *Am J Ind Med* 2006;49:474–91.
- [28] Sordillo JE, Sordillo JE, Hoffman EB, Celedón JC, Litonjua AA, Milton DK, et al. Multiple microbial exposures in the home may protect against asthma or allergy in childhood. *Clin Exp Allergy* 2010;40:902–10.
- [29] Lenters V, Basinas I, Beane-Freeman L, Boffetta P, Checkoway H, Coggon D, et al. Endotoxin exposure and lung cancer risk: a systematic review and meta-analysis of the published literature on agriculture and cotton textile workers. *Cancer Causes Control* 2009. <http://dx.doi.org/10.1007/s10552-009-9483-z>.
- [30] Mastrangelo G, Marzia V, Marcer G. Reduced lung cancer mortality in dairy farmers: is endotoxin exposure the key factor? *Am J Ind Med* 1996;30:601–9.
- [31] Mastrangelo G, Grange JM, Fadda E, Fedeli U, Buja A, Lange JH. Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. *Am J Epidemiol* 2005;161(June (11)):1037–46.
- [32] Laakkonen A, Pukkala E. Cancer incidence among Finnish farmers, 1995–2005. *Scand J Work Environ Health* 2008;34(February (1)):73–9.
- [33] Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, et al. Lung cancer risk among female textile workers exposed to endotoxin. *J Natl Cancer Inst* 2007;99:357–64.
- [34] Koskela RS, Klockars M, Jarvinen E. Mortality and disability among cotton mill workers. *Br J Ind Med* 1990;47:384–91.
- [35] Wernli KJ, Fitzgibbons ED, Ray RM, Gao DL, Li W, Seixas NS, et al. Occupational risk factors for esophageal and stomach cancers among female textile workers in Shanghai. *Chin Am J Epidemiol* 2006;163(8):717–25. 15.
- [36] De Roos AJ, Ray RM, Gao DL, Wernli KJ, Fitzgibbons ED, Ziding F, et al. Colorectal cancer incidence among female textile workers in Shanghai, China: a case-cohort analysis of occupational exposures. *Cancer Causes Control* 2005;16(10):1177–88.
- [37] Chang CK, Astrakianakis G, Thomas DB, Seixas NS, Ray RM, Gao DL, et al. Occupational exposures and risks of liver cancer among Shanghai female textile workers—a case-cohort study. *Int J Epidemiol* 2006;35(2):361–9.
- [38] Li W, Ray RM, Fitzgibbons ED, Seixas NS, Camp JE, Wernli KJ, et al. Occupational risk factors for pancreatic cancer among female textile workers in Shanghai. *Chin Occup Environ Med* 2006;63:788–93.
- [39] Ray RM, Gao DL, Li W, Wernli KJ, Astrakianakis G, Seixas NS, et al. Occupational exposures and breast cancer among women textile workers in Shanghai. *Epidemiology* 2007;18:383–92.
- [40] Liebers V, Raulf-Heimsoth M, Brüning T. Health effects due to endotoxin inhalation (review). *Arch Toxicol* 2008;82:203–10.
- [41] Allergy Therapeutics. Available at: www.allergytherapeutics.com/search.aspx?kw=pollinex+quattro (accessed in January 2013).
- [42] Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. *Expert Rev Vaccines* 2006;5(October (5)):617–29.
- [43] McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). *Drugs* 2006;66(7):931–8.
- [44] Cluff CW. Monophosphoryl Lipid A, (MPL) as an adjuvant for anti-cancer vaccines: clinical results. *Adv Exp Med Biol* 2009;667:111–23.
- [45] Glaxo Smith-Kline. Available at: <http://www.gsk.com/products/our-vaccines.html> (accessed on February 2013).
- [46] Hobohm U. Toward general prophylactic cancer vaccination. *BioEssays* 2009;31:1071–9.
- [47] Lundin JI, Checkoway H. Endotoxin and cancer. *Environ Health Perspect* 2009;117(9):1344–50.
- [48] Boffetta P. Endotoxins in lung cancer prevention. *JNCI* 2007;99(5):339.
- [49] Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. *Vaccine* 2008;26(December (51)):6630–8.
- [50] Keith RL. Chemoprevention of lung cancer. *Am Thorac Soc* 2009;6:187–93.